Strategic merger Global Genes merged with RARE-X in December 2022 to consolidate tools, technology and infrastructure for rare disease advocacy, signaling a broader platform opportunity for data services, donor engagement, and research partnerships.

Programs and pilots Recent launches like the RARE Navigator Program and HDVCH pilot indicate a push into patient services and care coordination, presenting opportunities to offer digital health solutions, patient journey analytics, and care navigation platforms.

Data collaboration Active partnerships such as the STARR study with STXBP1 Foundation and CHOP, leveraging the RARE-X data platform, create avenues to offer patient-reported data collection, data integration, and analytics services to other rare disease consortia.

Global expansion Past activity includes expanding facilities to Seoul, suggesting openness to international collaboration and regional partnerships, which could translate into localization services, global grant management, and multi-language outreach tools.

Funding and reach With substantial revenue and a broad nonprofit network, there is potential to bundle sponsorships, grant management solutions, and digital advocacy campaigns tailored to rare disease foundations seeking scalable impact and donor engagement.